Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Letter Medicine, General & Internal

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Sophie Caillard et al.

ANNALS OF INTERNAL MEDICINE (2022)

Article Multidisciplinary Sciences

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Lihong Liu et al.

Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.

NATURE (2022)

Add to Collection

Article Cell Biology

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

Xavier Charmetant et al.

Summary: Transplant recipients treated with immunosuppression have a lower response to COVID-19 vaccines, but previous infection with SARS-CoV-2 provides some protection. A study found that neutralizing anti-RBD IgG antibodies were the primary correlate of protection for transplant recipients. Immunosuppressive drugs may affect the generation of virus-specific B and T follicular helper cells. Administration of a third dose of SARS-CoV-2 mRNA vaccine improved the RBD-specific responses in transplant patients who had not previously responded to two doses of the vaccine.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Letter Urology & Nephrology

REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme

Didier Ducloux et al.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Letter Medicine, General & Internal

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Editorial Material Urology & Nephrology

COVID-19 vaccination in kidney transplant recipients

Sophie Caillard et al.

Summary: Kidney transplant recipients, due to therapeutic immunosuppression, have impaired immune responses to the COVID-19 mRNA vaccine, necessitating a personalized intensified vaccination approach for better protection.

NATURE REVIEWS NEPHROLOGY (2021)

Add to Collection

Article Immunology

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

Myron J Levin et al.

Open Forum Infectious Diseases (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Microbiology

Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods

Emma English et al.

Summary: In the early stages of the COVID-19 pandemic, numerous new serology tests were developed without rigorous evaluation, leading to inconsistent results. Robustly evaluated quantitative serology methods are needed, harmonized to a primary reference material for improved clinical decision making.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Urology & Nephrology

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

Sophie Caillard et al.

KIDNEY INTERNATIONAL (2020)

Add to Collection

Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Related references

Export Citation

Share Paper